NICE Onpattro approval puts Alnylam back in hATTR running
NICE issued the drug a preliminary ‘no’, back in December 2018.
Read More
Tag: Alynylam
Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis
The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
